Business
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to pro
About this update from Terns Pharmaceuticals, Inc.
[{"type":"image","alt":"Terns Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Terns Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/c88147929d4056469d083b437f21cbbe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nDZbzBBWIDLB9m8dQWqvlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c88147929d4056469d083b437f21cbbe","width":300,"height":61}},"lazy":false},{"type":"text","content":"CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026","length":95,"tagName":"p"},{"type":"text","content":"Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027","length":195,"tagName":"p"},{"type":"text","content":"TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025","length":88,"tagName":"p"},{"type":"text","content":"Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway into 2031","length":140,"tagName":"p"},{"type":"text","content":"FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that management will provide an update on 2026 priorities and program milestones during the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12th, 2026 at 3:45pm in San Francisco, CA.","length":398,"tagName":"p"},{"type":"text","content":"“Last year was transformative for Terns as we completed our transition to an oncology company anchored by our allosteric BCR-ABL inhibitor, TERN-701, for CML. Following compelling TERN-701 data at ASH in December, and our subsequent capital raise, we are in a strong position to advance TERN-701 towards pivotal trial initiation. Based on accelerating momentum in our CARDINAL trial, our goal for pivotal trials is to enroll patients more quickly than historical precedents in CML and to generate data that further strengthen the position of TERN-701 as a potential best-in-disease therapy across all lines of CML treatment,” said A...